A nonrandomized controlled trial performed at Nationwide Children's Hospital in Columbus, Ohio assessed the safety and efficacy of intravenous administration of rAAVrh74.MHCK7.micro‐dystrophin in DMD patients over 1 year. This evidence concerns the gene DMD and Duchenne muscular dystrophy.